Caplyta (lumateperone) and Vraylar (cariprazine) are brand-name oral capsules. They’re both prescribed for schizophrenia and depressive episodes of bipolar disorder. This article explains the main ...
Caplyta (lumateperone) and Vraylar (cariprazine) are prescription drugs used to treat schizophrenia and bipolar depression. Both drugs come as capsules that you take once per day. Caplyta and Vraylar ...
BEDMINSTER, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for ...
Intra-Cellular Therapies is doubling down on its Caplyta "Let in the Lyte" bipolar depression campaign, following its victory in this year's Fierce Madness Drug Ad Tournament. Riding high on this ...
Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. In a statistically ...
Caplyta (lumateperone) is a prescription drug used to treat schizophrenia in adults. It does not come as a generic drug. Caplyta comes as an oral capsule. The active ingredient in Caplyta is ...
What Is Caplyta, and Why Does It Matter? Caplyta (lumateperone) is a once‑daily atypical antipsychotic prescription medicine used to treat mental health conditions such as schizophrenia in adults. The ...
Intra-Cellular ITCI is focused on discovering, developing and commercializing small molecule drugs for treating neuropsychiatric and neurological disorders. The company currently has only one marketed ...
Nov 6 (Reuters) - The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson's (JNJ.N), opens new tab drug Caplyta as an add-on treatment for adults with major depressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results